

## Press Release

29 October 2010

# BELTAS Clinical Research Achieves 2nd Deloitte Fast 50 Award



Auckland company **BELTAS** Clinical Research is a 2010 Deloitte Fast 50 winner for the second year running after a period of strong growth.

**BELTAS**, a contract research organisation (CRO), manages and monitors clinical studies in hospitals and clinics throughout New Zealand, Australia and Europe.

The company also provides internationally accredited training and qualifications in Good Clinical Practice (GCP) for organisations considering or undertaking clinical trials.

“We’re thrilled at our placing as the 28<sup>th</sup> fastest growing company in New Zealand and 8<sup>th</sup> in our home base of Auckland,” says Managing Director Gerard Dunne.

“Our aim is to attract high quality medical research to New Zealand and Australia, for the benefit of patients, hospitals and clinical staff here. Both countries are ideal for clinical trials combining first world standards, responsiveness and a practical ethics and regulatory environment.

“All our clinical staff attain international accreditation, and in the clinical research field quality is our lifeblood.

“Tribute is also due to the increasing number of excellent dedicated research sites New Zealand boasts in our region, an attraction for worldwide biotechnology and medical device clients.”

In 2008, analyst estimates of the global market for CRO services ranged from US\$18 billion to US\$20 billion, with an annual growth rate of 10 to 15 percent.

**BELTAS**, founded in 2003 by Dunne, and Helmine Verhoeven (now based in The Netherlands), posted an increase of 290% over the 2010 Fast 50 three-year period.

**BELTAS** has been a New Zealand exporter from its first year of operation, using its internationally gained expertise to assist local biotechnology, drug, diagnostic and device companies to develop products within the Australasian region for the global market.

Matt McKendry, Deloitte’s Fast 50 leader, says **BELTAS** is one of several companies with a medical focus on this year’s Fast 50 list.

“**BELTAS** has carved out a niche focusing on attracting international medical research to Australasia from the US and Europe, but that alone isn’t enough to achieve this level of growth,” Mr McKendry says.

“It is clearly doing the basics extremely well and remaining firmly focused on the business strategy and vision. We keep finding among our Fast 50 businesses that taking that approach is a critical factor in their success.”

**BELTAS** staff are among founding members of the NZ Association of Clinical Research. The company sponsors the NZ Organisation for Rare Disorders, for children and adults with rare genetic conditions.

The Fast 50 is a Deloitte initiative which operates in more than 32 countries and territories around the world. It ranks businesses that choose to participate and is firmly established as a key barometer of New Zealand's emerging business market, celebrating its 10<sup>th</sup> year in NZ.

-ends-

For more information please contact:

Mr Gerard Dunne  
Managing Director  
**BELTAS**<sup>™</sup> Ltd  
Ph: +64 9 520 2410

[enquiries@beltas.com](mailto:enquiries@beltas.com)

[www.beltas.com](http://www.beltas.com)

[www.deloitte.com/view/en\\_NZ/nz/top-of-mind/deloitte-fast-50/2010-deloitte-fast-50/index.htm](http://www.deloitte.com/view/en_NZ/nz/top-of-mind/deloitte-fast-50/2010-deloitte-fast-50/index.htm)

Ends